EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PROTAC‑Mediated HMGCR Depletion Reprograms Lipid Metabolism in Breast Cancer to Potentiate Photoimmunotherapy via Ferroptosis

Tong Su, Guang Li, Yudong Guan, Qi Tian, Youzhi Qi, Yanqiu Zhang, Wenqian Wei, Xinxin Duan, Jiaxin Rui, Hongyan Zhu, Zengping Lin, Changchuan Xie und 7 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202521525 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Tong Su und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210009, China. Hauptthemen laut MEDLINE: Ferroptosis, Lipid Metabolism, Immunotherapy, Hydroxymethylglutaryl CoA Reductases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing health science and technology development special fund major project, Key Projects for the Development of New Medical Technologies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant lipid metabolism characterizes the progression of breast cancer. Statins, the canonical agents for modulating this pathway, have been associated with improved overall survival in patients with triple‐negative breast cancer (TNBC). However, their clinical benefit remains limited because the reversible inhibition of 3‐hydroxy‐3‐methylglutaryl‐CoA reductase (HMGCR) elicits a rebound in the mevalonate pathway and enables evasion of ferroptosis. Therefore, we developed a 170 nm self‐assembled nanomedicine (PRO‐P) that integrates an HMGCR‐targeting PROTAC (PRO) with a disulfide‐linked Pyropheophorbide‐a (Ppa) photosensitizer, enabling laser‐gated protein HMGCR degradation and photodynamic stress within one formulation. Under laser irradiation, PRO‐P catalytically depletes HMGCR while generating reactive oxygen species (ROS), collapsing the mevalonate/CoQ10‐GPX4 axis and redirecting lipids into ferroptosis. In 4T1 cells, PRO‐P enhanced cellular uptake by 1.34‐fold and elevated ROS by 9.5‐fold. Following intravenous administration in TNBC xenografts, PRO‐P achieved 92.5% tumor regression, eradicated pulmonary metastases, and elicited no systemic toxicity after single laser exposure. Immune profiling revealed remodeling of the microenvironment, with 2.6‐fold more CD8⁺ Granzyme‐B⁺ T cells, 4.3‐fold more mature dendritic cells, and fewer Tregs, thereby establishing durable memory. PRO‐P exploits multi‐omics–guided HMGCR targeting to convert lipid addiction into a redox–immunologic vulnerability, yielding a low‐toxicity therapy for TNBC and other lipid‐driven cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisLipid MetabolismImmunotherapyHydroxymethylglutaryl CoA ReductasesTriple Negative Breast NeoplasmsBreast NeoplasmsAnimalsFemaleMiceHumansCell Line, TumorPhotosensitizing AgentsReactive Oxygen Species

Stichwörter der Autor:innen

PROTAC (proteolysis‐targeting chimera)breast cancerferroptosislipid metabolismmevalonate pathwayphotoimmunotherapy

Substanzen

Hydroxymethylglutaryl CoA ReductasesPhotosensitizing AgentsHMGCR protein, humanReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Radiology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, 210009, China.
  • Department of Gynecological Oncology and Cervical Lesions, NHC Key Laboratory of Birth Defect For Research and Prevention (Hunan Provincial Maternal and Child Health Care Hospital), Changsha, 410013, China.
  • Center For Drug Research and Development, Guangdong Provincial Key Laboratory of Pharmaceutical Preparations Research and Evaluation, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
  • School of Stomatology, Zhongzhou Laboratory, Henan University, Kaifeng, Henan, 475004, China.
  • Department of Radiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210009, China.
  • United Imaging Healthcare Group Co., Ltd, Shanghai, 201807, China.

ORCID-Profile: Kun Chen

Förderung

  • Affiliated Drum Tower Hospital, Medical School of Nanjing University
  • Nanjing health science and technology development special fund major project
  • Key Projects for the Development of New Medical Technologies
  • Medical School of Nanjing University
  • National Natural Science Foundation of China
  • Special Support Program for High-level Talents of Zhongzhou Laboratory
  • Science and Technology Research Project of Henan Province
  • Science and Technology Innovation Program of Hunan Province

Zitieren

APA

Su, T., Li, G., Guan, Y., Tian, Q., Qi, Y., Zhang, Y., Wei, W., Duan, X., Rui, J., Zhu, H., Lin, Z., Xie, C., Xu, Z., Wu, Y., Peng, X., Wang, Z., Chen, K., Xin, X., & Zhang, B. (2026). PROTAC‑Mediated HMGCR Depletion Reprograms Lipid Metabolism in Breast Cancer to Potentiate Photoimmunotherapy via Ferroptosis. Advanced Science. https://doi.org/10.1002/advs.202521525

Vancouver

Su T, Li G, Guan Y, Tian Q, Qi Y, Zhang Y, et al. PROTAC‑Mediated HMGCR Depletion Reprograms Lipid Metabolism in Breast Cancer to Potentiate Photoimmunotherapy via Ferroptosis. Advanced Science. 2026. doi:10.1002/advs.202521525

BibTeX
@article{Su2026,
  author = {Su, Tong and Li, Guang and Guan, Yudong and Tian, Qi and Qi, Youzhi and Zhang, Yanqiu and Wei, Wenqian and Duan, Xinxin and Rui, Jiaxin and Zhu, Hongyan and Lin, Zengping and Xie, Changchuan and Xu, Zheni and Wu, Yaying and Peng, Xin and Wang, Zhenjie and Chen, Kun and Xin, Xiaoyan and Zhang, Bing},
  title = {PROTAC‑Mediated HMGCR Depletion Reprograms Lipid Metabolism in Breast Cancer to Potentiate Photoimmunotherapy via Ferroptosis},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202521525}
}
Kostenlos starten →